• Cosmos Health signed a five-year contract manufacturing agreement with Viofar for about 2,500,000 units of ROSARTIA.
• Annual contracted volume set at roughly 500,000 units across multiple strengths of the rosuvastatin-based statin therapy.
• Cumulative contract manufacturing orderbook rose above 27,500,000 units, up from more than 25,000,000 units reported in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609111110ACCESSWRNAPR_____1219830) on September 11, 2026, and is solely responsible for the information contained therein.